tbuckley/cabot-search huggingface dataset:
Abstract P2-02-06: Impact of apoptotic circulating tumor cells in metastatic breast cancer
Authors: M Wallwiener, TM Deutsch, S Riethdorf, AD Hartkopf, F-A Taran, A Trumpp, S Brucker, F Schütz, J Rom, K Pantel, A Schneeweiss
Journal: Cancer Research (2016)

Abstract Background Circulating tumor cells (CTC) are a heterogeneous cell population and an independent negative prognostic factor for progression-free (PFS) and overall survival (OS) in patients with metastatic breast cancer (MBC). The study aimed to prospectively assess CTC status for the subtypes apoptotic CTC (aCTC) and intact CTC (iCTC) at baseline (CTCBL) and after one cycle of a new line of systemic therapy (CTC1C). Changes from CTCBL to CTC1C (CTC kinetics, CTCKIN) were evaluated for their utility in predicting response, progression-free (PFS) and overall survival (OS). Methods 423 MBC patients were included in a prospective trial prior to a new regimen of treatment. Intact and apoptotic CTC were analyzed at baseline (CTCBL) and after one cycle of systemic therapy (CTC1C) using CellSearch™ (Veridex) and morphologic criteria. Samples with ≥5 CTC/7.5ml blood were regarded as positive. Therapy response was assessed using the RECIST-criteria on three-monthly radiological controls. CTCKIN were characterized by ≥25% change from CTCBL to CTC1C to differentiate stable, increased and decreased CTC kinetic. Results 35% of patients were iCTCBL-positive and 28% aCTCBL-positive at baseline (CTCBL). PFS and OS differ significantly between the iCTCBL-positive and the iCTCBL-negative group (PFS 4.5 vs. 8.0; OS 12.5 vs. 27.2 (months)). Positive aCTC in conjunction with positive iCTCBL at baseline has worst prognostic impact (PFS 6.3; OS 8.7). Regarding the CTCKIN (BL to 1C), aCTC-decrease (≥25%) is a positive prognostic factor compared to aCTC-stable and aCTC-increase (PFS 7.6 vs. 3.7; 3.3 and OS 21.0 vs. 4.8; 5.7). Decreasing aCTCKIN shows favorable prognostic impact versus decreasing iCTCKIN (PFS 7.6 vs. 5.9 and OS 21.0 vs 16.4). Conclusion Elevated aCTC levels at baseline have an unfavorable prognostic impact on both OS and PFS in conjunction with elevated iCTC. Additionally, the decrease of aCTC is a relevant prognostic value for systemic therapy response. aCTCKIN allows better differentiation for therapy response in patients with positive CTC-status at baseline. Differentiated enumeration of intact and apoptotic CTC should be considered in clinical application. Citation Format: Wallwiener M, Deutsch TM, Riethdorf S, Hartkopf AD, Taran F-A, Trumpp A, Brucker S, Schütz F, Rom J, Pantel K, Schneeweiss A. Impact of apoptotic circulating tumor cells in metastatic breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-02-06.
Abstract IA17: Delivering on the promise of personalized medicine
Authors: Gordon B. Mills
Journal: Clinical Cancer Research (2016)

Abstract The realization of the promise of personalized molecular medicine requires efficient development and implementation of novel targeted therapeutics linked to molecular markers able to identify patients most likely to benefit. An efficient integration of DNA, RNA and protein information content will be needed to identify patients likely to respond to particular therapies. The plethora of aberrations present in each tumor, the need to distinguish drivers from passengers, and the combinatorial effects of aberrations on critical cellular functions represent key challenges. The overall likelihood of response to therapy represents the interaction between predictors of sensitivity and predictors of resistance. Resistance can be pre-existing, adaptive, or acquired. Resistance can also occur through heterogeneity of molecular changes within the tumor and metastases. Adaptive resistance, which is the consequence of activation of homeostatic loops and phylogenetically conserved stress responses, provides a potential therapeutic liability that can be leveraged for rational combinatorial therapy. Thus a comprehensive analysis of patient tumors before, during and after treatment should become the standard of practice. Testing these precepts will require the development and implementation of novel trial designs. It is likely that we will need to increase the size of phase I and II trials to allow the identification and validation of molecular markers at the same time as the initial evaluation the toxicity and efficacy of targeted therapeutics. This will come with the advantage much smaller phase III trials of patients selected for the likelihood to respond accelerating the approval of effective targeted therapeutics. Citation Format: Gordon B. Mills. Delivering on the promise of personalized medicine. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy; Jun 13-16, 2015; Salt Lake City, UT. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(1_Suppl):Abstract nr IA17.
RESULTS OF SURGICAL TREATMENT OF UNILATERAL CARCINOMA OF BREAST IN WOMEN
Authors: S W HARRINGTON
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TETRACYCLINE DEPOSITS IN MINERALIZED TISSUE
Authors: H K BEECHER
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Studies on the Mechanism of Immunological Enhancement of Tumor Grafts
Authors: Michael Feldman, Amiela Globerson
Journal: JNCI Journal of the National Cancer Institute (1960)

The mechanism of immunological enhancement of tumor homografts by heteroimmune serum was studied, particularly the immunological properties of the active antiserum and its mode of action. Tumor homografts, enhanced by heteroimmune serum, were shown to elicit an intense homograft reaction, while growing progressively in foreign hosts. This reaction is manifested both by the production of isohemagglutinins with enhanced 6C3HED lymphosarcoma and by the increased resistance of the host, i.e., transplantation immunity produced by enhanced Sarcoma SBL1. The enhancement of tumor homografts was thus attributed to a capacity to resist transplantation immunity induced in the tumor cells and not to suppression of the host's resistance. This implies a direct action of the enhancing antibodies on the tumor cells. The direct action was further supported by the fact that heteroimmune serum enhanced the growth of tumor isografts. Passive transfer of immunity through lymph nodes activated by tumor homografts of Sarcoma MC1M revealed that after a prolonged exposure the same lymph nodes producing transplantation immunity can produce enhancing antibodies. The experimental data obtained in the present study might explain immunological enhancement if it is assumed that the enhancing antibodies stimulate an augmented synthesis of their homologous antigen in the tumor cells. Such an increased production of antigen might explain both the augmented growth of enhanced tumor isografts and the resistance of enhanced tumor homografts to transplantation immunity.
THE SURGICAL TREATMENT OF TYPHOID CARRIERS
Authors: F MICEK, J HRUZIK, P CERNAK
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Art: The Time of Our Lives
Authors: S. A Spence
Journal: BMJ (1999)

Exhibition at the New Museum of Contemporary Art, New York, until 17 October

Situated at the lower end of Broadway, where it runs through NoHo and SoHo (north and south of Houston Street, respectively), the New Museum of Contemporary Art is currently hosting two exhibitions, one of which is purportedly concerned with ageing. Specifically, it is meant to remind us that we will all grow old (if we are fortunate) and that older people are disenfranchised by modern society; more specifically, by modern Western society. The catalogue essays are replete with intimations of ageing that the curators have detected in themselves (such as “elder moments,” when one loses track of what it was one wanted to say), and more alarmingly, of ageism, reified in the attitudes portrayed in soap operas towards comic elders, who send themselves …
Anal Cancer
Authors: John L. Zeller
Journal: JAMA (2008)

Anal CancerA nal cancer is a disease in which malignant (cancer) cells form in the tissues of the anus.The anus is located at the end of the large intestine, below the rectum, through which solid waste leaves the body.The anus is formed partly from the outer skin layers and partly from the intestine.The anal canal, the part of the anus between the rectum and the anal opening, is about 1½ inches long.Anal carcinoma (cancer) is unique and can be distinguished from all other gastrointestinal tumors.It is mainly a local-regional cancer, with a metastatic potential (possibility of spreading to other body tissues) in only 15% of patients.The April 23/30, 2008, issue of JAMA includes an article evaluating current therapies for the treatment of anal carcinoma.
Depressed mood during pregnancy and the puerperium: clinical recognition and implications for clinical practice
Authors: B R Saks, J B Frank, T L Lowe, W Berman, F Naftolin, D J Cohen
Journal: American Journal of Psychiatry (1985)

Mild to moderate depression is common among women during the first 3 months postpartum. The authors studied 20 normal pregnant women in the hope of finding valid predictors of postpartum mood disorder. The subjects rated their level of emotions and various depressive symptoms at 26 and 36 weeks of pregnancy and filled out a brief questionnaire about the emotional circumstances of their pregnancy. The mood scales were repeated at 2 days and 6 weeks postpartum, along with a clinical interview. The antepartum mood scale identified women with postpartum depression and differentiated this condition from the more common, transient postpartum blues. Certain psychosocial variables also predicted postpartum distress. The authors discuss the implications of these findings, emphasizing the feasibility and necessity of routine screening for mood disturbances in prenatal and puerperal women.
Recognizing DNA
Authors: Nadia Rosenthal
Journal: New England Journal of Medicine (1995)

One of the most startling discoveries in the wake of the cloning of the human β-globin gene nearly 20 years ago was that many patients with thalassemia carried mutations outside the gene's coding sequence. In certain cases the change affected just one nucleotide base in a region of DNA upstream of where transcription of the β-globin starts. Yet the amount of β-globin produced by the red cells of these patients was drastically reduced. It was difficult to imagine how such a subtle change could shut down a whole assembly line. What function could a single nucleotide perform that was so . . .
Long-term in vivo expression of a murine adenosine deaminase gene in rhesus monkey hematopoietic cells of multiple lineages after retroviral mediated gene transfer into CD34+ bone marrow cells
Authors: DM Bodine, T Moritz, RE Donahue, BD Luskey, SW Kessler, DI Martin, SH Orkin, AW Nienhuis, DA Williams
Journal: Blood (1993)
F-18 FDG Uptake in the Large Arteries
Authors: MIJIN YUN, DAVID YEH, LOUIS I. ARAUJO, SUNYOUNG JANG, ANDREW NEWBERG, ABASS ALAVI
Journal: Clinical Nuclear Medicine (2001)

Purpose The cellular components of the atherosclerotic plaque, such as macrophages, exhibits high glucose metabolic activity. The aim of this study was to show the frequency of vascular uptake and possibly to explain the significance of this finding on fluorodeoxyglucose (FDG) positron emission tomographic (PET) scans. Methods We evaluated the presence of FDG vascular uptake in 132 consecutive patients undergoing whole-body PET scans and 5 patients who had only lower extremity scans. The presence of vascular FDG uptake was assessed in the abdominal aorta, iliac, and proximal femoral arteries on the 132 whole-body scans, whereas only the femoral and the popliteal arteries were examined on the leg scans. The patients' ages ranged from 20 to 80 years, and they were divided into three age groups: 35 patients were younger than 40 years (group 1; mean age, 32.4 years), 48 patients were 41 to 60 years (group 2; mean age, 50.3 years), and 54 patients were older than 60 years (group 3; mean age, 70.3 years). Results Fifty percent (69 of 137) of the total population showed vascular FDG uptake in at least one vessel. Thirty-four percent (12 of 35) of group 1, 50% (24 of 48) of group 2, and 61% (33 of 54) of group 3 showed vascular wall uptake (P = 0.017 between groups 1 and 3). In addition, the correlation between the mean age of the age groups and the prevalence of FDG vascular uptake is strong (r = 0.99). Conclusions Vascular FDG uptake is present in 50% of the patients examined for this study, with an increased prevalence in older patients. This vascular uptake might be explained by smooth muscle metabolism in the media, subendothelial smooth muscle proliferation from senescence, and the presence of macrophages within the atherosclerotic plaque. The relative contribution of these sources needs further investigation.
Tc-99m MDP and Ga-67 citrate scintigraphic findings in sarcoidosis with osseous involvement.
Authors: S S Sun, S C Tsai, C J Hung, P P Tsai, C H Kao
Journal: Clinical Nuclear Medicine (2001)

SUN, SHUNG-SHUNG M.D.; TSAI, SHIH-CHUAN M.D.; HUNG, CHIH-JEN M.D.; TSAI, PO-PANG M.D.; KAO, CHIA-HUNG M.D. Author Information
Epstein-Barr virus (EBV)-associated lymphoproliferations in severe combined immunodeficient mice transplanted with Hodgkin's disease lymph nodes: implications of EBV-positive bystander B lymphocytes rather than EBV-infected Reed-Sternberg cells
Authors: F Meggetto, C Muller, S Henry, J Selves, B Mariame, P Brousset, TA Saati, G Delsol
Journal: Blood (1996)
Inferior Vena Cava Filters in the Cancer Patient: Current Use and Indications
Authors: Todd M. Getzen, John E. Rectenwald
Journal: Journal of the National Comprehensive Cancer Network (2006)

Deep venous thrombosis and thromboembolism are significant health risks, with high rates of morbidity and mortality. Chronically ill and hospitalized patients, particularly those with cancer, have a high risk for developing these conditions. Mechanical inferior vena cava (IVC) filtration has been standard care for patients with these conditions in whom anticoagulation therapy is contraindicated or has failed. This article reviews caval filters and the current indications for using mechanical IVC filters, including retrievable versus permanent filters, focusing on their use in treating venous thromboembolism in cancer patients.
Putative Physiopathological Explanation for the “Sock Sign” in Bone Scans
Authors: Carole de Vaugelade, Jean-Baptiste Pinaquy, Philippe Fernandez, Laurence Bordenave, Elif Hindie, Paolo Zanotti-Fregonara
Journal: Clinical Nuclear Medicine (2016)

Four patients were referred to our department to undergo a bone scan for suspected reflex sympathetic dystrophy in the upper limbs. After TC-HMDP injection in the foot, they developed a "sock sign," defined by highly increased uptake in the injected lower limb. The sock sign has been previously described in only 1 case in the literature and attributed to intra-arterial injection. Our images suggest that the sock sign might instead be the consequence of tracer extravasation at the injection site.
Immunohistochemical Markers Defined by Monoclonal Antibodies and Response to Bacillus Calmette-Guérin Endovesical Immunotherapy for Superficial Bladder Tumors
Authors: Thierry A. Flam, Dominique K. Chopin, Christian Leleu, Claude C. Abbou, Adolphe Steg, Sharon Deslignères, Liliane Boccon-Gibod
Journal: European Urology (1990)
Predicting Prostate-Specific Antigen Recurrence Established: Now, Who Will Survive?
Authors: Anthony V. D’Amico
Journal: Journal of Clinical Oncology (2002)

Article Tools EDITORIALS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.15.3188 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12149288 Predicting Prostate-Specific Antigen Recurrence Established: Now, Who Will Survive? Anthony V. D’AmicoxAnthony V. D’AmicoSearch for articles by this author Show More Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA https://doi.org/10.1200/JCO.2002.20.15.3188 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical Oncology
Case 15-2016
Authors: Michael Ronthal, Nagagopal Venna, George J. Hunter, Matthew P. Frosch
Journal: New England Journal of Medicine (2016)

A 32-year-old man presented with a 1-year history of olfactory hallucinations and a 6-week history of intermittent numbness and paresthesias on the left side. MRI revealed a nodular focus of enhancement in the medial right temporal lobe. A diagnostic procedure was performed.
Abstract 809: BrafV637E mutation as an early change in hepatocarcinogenesis induced by neonatal treatment with diethylnitrosamine in B6C3F1 mice
Authors: Masahiro Yamamoto, Hiroki Tanaka, Xin Bing, Yuji Nishikawa, Kohsuke Yamazaki, Keiko Shimizu, Katsuhiro Ogawa
Journal: Cancer Research (2015)

Abstract Neonatal treatment of B6C3F1 mice with diethylnitrosamine (DEN) is often employed as an experimental model for hepatic tumors. In this model, microscopic preneoplastic foci emerge in the early stage and subsequently progress into adenomas, from which hepatocellular carcinoma (HCC) is finally developed. We detected the BrafV637E mutation, that is correspondent to the human BrafV600E mutation, in 4/4 DEN-induced hepatic tumors at 13 months after DEN treatment by whole exome analysis, and further in 16/17 (94.1%) late tumors by the PCR-direct sequencing method. By microdissection, the BrafV637E mutation was also detected in 16/18 (88.8%) and 22/28 (78.5%) microscopic lesions (preneoplastic foci and microadenomas) respectively at 5 and 8-9 months after DEN treatment. Meanwhile, although the BrafV637E mutation was detected in 5/7 (71.4%) hepatic tumors induced by neonatal DEN treatment followed by repeated CCl4 administration, it was not found in 24 hepatic tumors induced by CCl4 alone and 6 spontaneous hepatic tumors in B6C3F1 mice, indicating that the BrafV637E mutation is specific to the DEN-initiated hepatic tumors, presumably being derived from the genotoxic action of DEN. The DEN-induced tumors showed hyperphosphorylation of MEK and ERK1/2, indicating that the BrafV637E mutation activated the downstream MAPK pathway. Furthermore, the DEN-induced tumors overexpressed the pro-survival/pro-proliferative cytokines/chemokines such as complement C5/C5a, soluble intercellular adhesion molecule (sICAM-1), IL-1 receptor antagonist (IL-1ra) and chemokine CXCL9 as well as the oncogene-induced senescence (OIS) markers, p15Ink4b and p19Arf mRNAs, suggesting that the BrafV637E mutation might influence the gene expression that is involved either in cellular growth/survival or OIS. Transgenic mice expressing BrafV637E specifically in the liver under the control of albumin promoter showed enlarged hepatic mass as large as 4-5 times of normal liver, and whole liver was consisted of small basophilic hepatocytes resembling the cells in the early preneoplastic lesions induced by neonatal treatment with DEN. These results indicate that the BrafV637E mutation plays a pivotal role in the DEN-induced hepatocarcinogenesis. Citation Format: Masahiro Yamamoto, Hiroki Tanaka, Xin Bing, Yuji Nishikawa, Kohsuke Yamazaki, Keiko Shimizu, Katsuhiro Ogawa. BrafV637E mutation as an early change in hepatocarcinogenesis induced by neonatal treatment with diethylnitrosamine in B6C3F1 mice. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 809. doi:10.1158/1538-7445.AM2015-809